ArticleThe Prostate2018
Correlations of SELENOF and SELENOP genotypes with serum selenium levels and prostate cancer.
Article in The Prostate, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 28 citations in OpenAlex.
- Trial
- Selenoproteins: Minute yet vital players governing cellular fate.Genes & diseases · 2026Review
- Contributions of selenoproteins to breast cancer etiology and racial disparity.Cancer causes & control : CCC · 2026Article
- A U-shaped association between blood selenium levels and prostate cancer: findings of a case-control study among Nigerian men.Scientific reports · 2025Article
- Dietary impacts on prostate cancer immunotherapy.Immunotherapy · 2025Review
- Selenium as a Modulator of Redox Reactions in the Prevention and Treatment of Cardiovascular Diseases.Antioxidants (Basel, Switzerland) · 2024Review
- Current Understanding of Human Polymorphism in Selenoprotein Genes: A Review of Its Significance as a Risk Biomarker.International journal of molecular sciences · 2024Review
- Selenium and Selenoproteins in Health.Biomolecules · 2023Review
- Distinct Roles of SELENOF in Different Human Cancers.Biomolecules · 2023Review
- Article
- SELENOF is a new tumor suppressor in breast cancer.Oncogene · 2022Article
- Loss of SELENOF Induces the Transformed Phenotype in Human Immortalized Prostate Epithelial Cells.International journal of molecular sciences · 2021Article
- Integrated Analysis to Study the Relationship between Tumor-Associated Selenoproteins: Focus on Prostate Cancer.International journal of molecular sciences · 2020Article
- The Interaction between Dietary Selenium Intake and Genetics in Determining Cancer Risk and Outcome.Nutrients · 2020Review
- Selenoproteins of the Human Prostate: Unusual Properties and Role in Cancer Etiology.Biological trace element research · 2019Review
- GPX1 Localizes to the Nucleus in Prostate Epithelium and its Levels are not Associated with Prostate Cancer Recurrence.Antioxidants (Basel, Switzerland) · 2018Article
- Correlations of SELENOF and SELENOP genotypes with serum selenium levels and prostate cancer.The Prostate · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundSelenium status is inversely associated with the incidence of prostate cancer. However, supplementation trials have not indicated a benefit of selenium supplementation in reducing cancer risk. Polymorphisms in the gene encoding selenoprotein 15 (SELENOF) are associated with cancer incidence/mortality and present disproportionately in African Americans. Relationships among the genotype of selenoproteins implicated in increased cancer risk, selenium status, and race with prostate cancer were investigated.
methodsTissue microarrays were used to assess SELENOF levels and cellular location in prostatic tissue. Sera and DNA from participants of the Chicago-based Adiposity Study Cohort were used to quantify selenium levels and genotype frequencies of the genes for SELENOF and the selenium-carrier protein selenoprotein P (SELENOP). Logistic regression models for dichotomous patient outcomes and regression models for continuous outcome were employed to identify both clinical, genetic, and biochemical characteristics that are associated with these outcomes.
resultsSELENOF is dramatically reduced in prostate cancer and lower in tumors derived from African American men as compared to tumors obtained from Caucasians. Differing frequency of SELENOF polymorphisms and lower selenium levels were observed in African Americans as compared to Caucasians. SELENOF genotypes were associated with higher histological tumor grade. A polymorphism in SELENOP was associated with recurrence and higher serum PSA.
conclusionsThese results indicate an interaction between selenium status and selenoprotein genotypes that may contribute to the disparity in prostate cancer incidence and outcome experienced by African Americans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.